ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Efficacy and safety of Kanglaite plus EGFR-TKI in the treatment of advanced non-small cell lung cancer: A meta-analysis of 13 RCTs

Li, Dailong; Li, Wanqiang; Xu, Lu; Che, Yuan; Cheng, Chunlai*武汉大学; 1
Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries2022-12-16DOI: 10.1097/MD.0000000000032169
10阅读
引用收藏
分享

摘要

Background:Kanglaite (KLT) is a Chinese medicine antitumor drug independently developed in China, which has been widely used in the treatment of advanced non-small cell lung cancer (NSCLC). The purpose of this study was to systematically evaluate the efficacy and safety of KLT plus epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in the treatment of advanced NSCLC. Methods:Up to September 1, 2022, the databases of PubMed, EMBASE, Cochrane Library, ClinicalTrials.gov, China National Knowledge Infrastructure, Chinese Biomedical Literature, China Science and Technology Journal, and Wanfang were searched, and the randomized controlled clinical trials (RCTs) of KLT plus EGFR-TKI in the treatment of advanced NSCLC were included. Two researchers independently screened the literature, extracted data, and evaluated the quality of the included literature. Revman5.4 software was used for meta-analysis. Results:A total of 1057 patients were included in 13 RCTs. The results of meta-analysis showed that KLT plus EGFR-TKI could improve the objective response rate (ORR) (risk ratio (RR) confidence interval (CI) [RR = 1.54, 95% CI: 1.27-1.86, P < .00001]), the disease control rate (DCR) (RR = 1.23, 95% CI: 1.14-1.32, P < .00001), and quality of life (QOL) (RR = 1.79, 95% CI: 1.36-2.36, P < .0001) in patients with advanced NSCLC. The percentages of CD3(+)T cells (standardized mean difference [SMD = 2.37, 95% CI: 0.80-3.93, P = .003]), CD4(+)T cells (SMD = 1.39, 95% CI: 0.85-1.93, P < .00001), NK cells (SMD = 1.59, 95% CI: 0.88-2.30, P < .0001), and CD4(+)/CD8(+)ratio (SMD = 0.37, 95% CI: 0.19-0.55, P < .0001) were also increased. However, the results of subgroup analysis showed that in patients with EGFR mutation NSCLC, compared with EGFR-TKI alone, KLT plus EGFR-TKI did not significantly increase ORR and DCR (RR = 1.43, 95% CI: 0.88-2.32, P = .15; RR = 1.07, 95% CI: 0.96-1.20, P = .21). In terms of adverse events of drugs, the incidence of diarrhea, rash, anorexia, nausea and vomiting, liver and renal function damage of KLT plus EGFR-TKI was similar to that of EGFR-TKI alone (P > .05). Conclusion:KLT plus EGFR-TKI has some clinical benefits and good safety compared with EGFR-TKI alone in the treatment of advanced NSCLC. However, it seems that patients with EGFR mutations do not get significant clinical benefits, and more high-quality RCTs are needed to prove the efficacy of the combined regimen.

学科与关键词

关键词
EGFRKanglaitemeta-analysisnon-small cell lung cancerTKI
相关
加载中…
  • Efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer: A meta-analysis of randomized controlled trials
    Li, Dailong; Yao, Ling; Xu, Lu; Li, Wanqiang; Che, Yuan*Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries, 2022, 101(48).
  • EGFR抑制剂治疗EGFR突变型晚期非小细胞肺癌的Meta分析
    张蓉; 陈薇雅; 甘洁民; 赵虎; 顾兆祥检验医学, 2013, (06): 506.
  • Influence of Smoking Habits on the Efficacy of EGFR-TKI Therapy in Patients with Advanced NSCLC: A Systematic Review and Meta-Analysis
    Mo, Zexun; Ye, Meifeng; He, Hua; Huang, Xiaomei; Guo, Weihong; Zhao, Ziwen*; Li, Yujun*; Wei, Shuquan*Clinical Medicine Insights: Oncology , 2023, 17: 11795549231215968.
查看全部 →

发表信息

论文状态
公开发表
期刊
Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries
发表日期
2022-12-16
卷期
第 101 卷, 第 50 期
DOI
10.1097/MD.0000000000032169
语言
ENGLISH
期刊等级
4区
成果收录
SCIE

作者

  • L

    Li, Dailong (第一作者)

  • L

    Li, Wanqiang

    1 · china three gorges univ

查看全部 5 位作者收起作者
  • X

    Xu, Lu

    wuhan univ

  • C

    Che, Yuan

  • C

    Cheng, Chunlai (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417